Catalyst Funds Management Pty Ltd Takes Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Catalyst Funds Management Pty Ltd purchased a new stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) during the fourth quarter, Holdings Channel reports. The firm purchased 10,500 shares of the biotechnology company’s stock, valued at approximately $47,000.

Other large investors have also recently bought and sold shares of the company. KBC Group NV grew its position in Ironwood Pharmaceuticals by 59.3% in the third quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 3,198 shares during the period. Journey Strategic Wealth LLC acquired a new position in Ironwood Pharmaceuticals in the fourth quarter worth $45,000. SG Americas Securities LLC acquired a new position in Ironwood Pharmaceuticals in the fourth quarter worth $53,000. CIBC Asset Management Inc acquired a new position in Ironwood Pharmaceuticals in the fourth quarter worth $53,000. Finally, Wolverine Trading LLC acquired a new position in Ironwood Pharmaceuticals in the third quarter worth $51,000.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, CEO Thomas A. Mccourt sold 139,064 shares of the stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $244,752.64. Following the transaction, the chief executive officer now owns 1,160,634 shares of the company’s stock, valued at approximately $2,042,715.84. This represents a 10.70 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CMO Michael Shetzline sold 41,269 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $1.76, for a total value of $72,633.44. Following the completion of the transaction, the chief marketing officer now directly owns 554,007 shares in the company, valued at $975,052.32. The trade was a 6.93 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 192,381 shares of company stock valued at $338,591. 12.90% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have commented on the company. StockNews.com raised Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday. JMP Securities reduced their price objective on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating on the stock in a research note on Thursday, January 30th. Finally, Craig Hallum reduced their price objective on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, January 22nd. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $8.60.

Ironwood Pharmaceuticals Stock Down 1.3 %

Shares of IRWD opened at $1.49 on Monday. Ironwood Pharmaceuticals, Inc. has a 12-month low of $1.34 and a 12-month high of $9.23. The firm has a market capitalization of $238.44 million, a PE ratio of -49.67 and a beta of 0.37. The stock’s fifty day simple moving average is $2.56 and its 200-day simple moving average is $3.60.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.08). Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The firm had revenue of $90.55 million for the quarter, compared to analyst estimates of $93.85 million. Analysts anticipate that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current year.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.